



- (51) **International Patent Classification:**
A61B 5/00 (2006.01) *A61B 5/11* (2006.01)
- (21) **International Application Number:**
PCT/AU2016/050346
- (22) **International Filing Date:**
9 May 2016 (09.05.2016)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/160,937 13 May 2015 (13.05.2015) US
- (71) **Applicant:** RESMED LIMITED [AU/AU]; 1 Elizabeth Macarthur Drive, Bella Vista, New South Wales 2153 (AU).
- (72) **Inventor:** WANG, Ning; c/- ResMed Limited, 1 Elizabeth Macarthur Drive, Bella Vista, New South Wales 2153 (AU).
- (74) **Agents:** DAVIDSON, Geoffrey Robert et al.; Halfords IP, 1 Market Street, Sydney, New South Wales 2000 (AU).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]


(54) **Title:** SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS, AND MONITORING OF SLEEP-DISORDERED BREATHING

FIG. 6

(57) **Abstract:** A method and system are disclosed for use in monitoring/screening/diagnosing sleep or wake state of a subject or patient. The method generally includes monitoring the patient's activity during one or more sleep sessions comprising a plurality of intervals known as epochs. The sleep/wake state of the subject is determined during each epoch of the session using actigraphy data obtained during the monitoring session. The actigraphy data provides information about the activity of a patient during an epoch. The sleep or wake state is determined based on a ratio of the activity count during an epoch to the activity count during a preceding epoch. If the ratio is greater than a first activity threshold, then a "wake" indication may be provided by, for example, the system. Alternatively, or additionally, a "wake" indication may be determined if the activity count during the epoch is greater than a threshold.

WO 2016/179651 A1



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, **Published:**
GW, KM, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*

SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS, AND MONITORING OF SLEEP-DISORDERED BREATHING

1 CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62/160,937, entitled “Systems and Methods for Screening, Diagnosis, and Monitoring of Sleep-Disordered Breathing,” filed May 13, 2015, the entire disclosure of which is hereby incorporated herein by reference.

2 STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] Not Applicable

3 THE NAMES OF PARTIES TO A JOINT RESEARCH DEVELOPMENT

[0003] Not Applicable

4 SEQUENCE LISTING

[0004] Not Applicable

5 BACKGROUND OF THE TECHNOLOGY

5.1 FIELD OF THE TECHNOLOGY

[0005] The present technology relates to one or more of the screening, diagnosis, and monitoring of respiratory-related disorders. The present technology also relates to medical devices or systems, and their use.

5.2 DESCRIPTION OF THE RELATED ART

5.2.1 Human Respiratory System and its Disorders

[0006] The respiratory system of the body facilitates gas exchange. The nose and mouth form the entrance to the airways of a patient.

[0007] The airways include a series of branching tubes, which become narrower, shorter and more numerous as they penetrate deeper into the lung. The primary function of the lung is gas exchange, allowing oxygen to move from the air into the

venous blood and carbon dioxide to move out. The trachea divides into right and left main bronchi, which further divide eventually into terminal bronchioles. The bronchi make up the conducting airways, and do not take part in gas exchange. Further divisions of the airways lead to the respiratory bronchioles, and eventually to the alveoli. The alveolated region of the lung is where the gas exchange takes place, and is referred to as the respiratory zone. See “*Respiratory Physiology*”, by John B. West, Lippincott Williams & Wilkins, 9th edition published 2011.

[0008] A range of respiratory disorders exist. Certain disorders may be characterised by particular events, e.g., apneas, hypopneas, and hyperpneas.

[0009] Obstructive Sleep Apnea (OSA), a form of Sleep Disordered Breathing (SDB), is characterized by events including occlusion or obstruction of the upper air passage during sleep. It results from a combination of an abnormally small upper airway and the normal loss of muscle tone in the region of the tongue, soft palate and posterior oropharyngeal wall during sleep. The condition causes the affected patient to stop breathing for periods known as apneas, typically of 30 to 120 seconds in duration, sometimes 200 to 300 times per night. OSA often causes excessive daytime somnolence, and it may cause cardiovascular disease and brain damage. OSA is a common disorder, particularly in middle aged overweight males, although a person affected may have no awareness of the problem. See US Patent No. 4,944,310 (Sullivan).

[0010] Cheyne-Stokes Respiration (CSR) is another form of sleep disordered breathing. CSR is a disorder of a patient's respiratory controller in which there are rhythmic alternating periods of waxing and waning ventilation known as CSR cycles. CSR is characterised by repetitive de-oxygenation and re-oxygenation of the arterial blood. It is possible that CSR is harmful because of the repetitive hypoxia. In some patients CSR is associated with repetitive arousal from sleep, which causes severe sleep disruption, increased sympathetic activity, and increased afterload. See US Patent No. 6,532,959 (Berthon-Jones).

5.2.2 Diagnosis and Monitoring Systems

[0011] Clinical experts may be able to screen, diagnose, or monitor patients adequately based on personal observation. However, there are circumstances where a

clinical expert may not be available, or a clinical expert may not be affordable. In some circumstances different clinical experts may disagree on a patient's condition. A given clinical expert may apply a different standard at different times. With a busy clinical practice, a clinician may have difficulty keeping up with evolving patient management guidelines.

[0012] Polysomnography (PSG) is a conventional system for diagnosis and prognosis of cardio-pulmonary disorders, and typically involves expert clinical staff to both apply and interpret. PSG typically involves the placement of 15 to 20 contact sensors on a person in order to record various bodily signals such as electroencephalography (EEG), electrocardiography (ECG), electrooculography (EOG), electromyography (EMG), etc. However, while they may be suitable for their usual application in a clinical setting, such systems are complicated and potentially expensive, and / or may be uncomfortable or impractical for a patient at home trying to sleep.

[0013] A more convenient screening / diagnosis / monitoring system for home use comprises a nasal cannula, a pressure sensor, a processing device, and recording means. A nasal cannula is a device comprising two hollow open-ended projections that are configured to be inserted non-invasively a little way into a patient's nares so as to interfere as little as possible with the patient's respiration. The hollow projections are in fluid communication with a pressure transducer via a Y-shaped tube. The pressure transducer provides a data signal representative of the pressure at the entrance to the patient's nares (the nasal pressure). Nasal pressure is a satisfactory proxy for the nasal flow rate because the nasal pressure signal is comparable in shape to a nasal flow rate signal.

[0014] The processing device may be configured to analyse the nasal pressure signal from the pressure transducer in real time in order to monitor the patient's breathing. By contrast, diagnosis need not be performed in real time. The recording means is therefore configured to record the nasal pressure signal from the pressure transducer for later off-line analysis for diagnosis purposes.

[0015] The analysis of the nasal pressure signal may seek to identify apneas and hypopneas during a screening / diagnosis / monitoring session. The total number of

apneas and hypopneas divided by the length of the monitoring session gives an index of severity of SDB known as the apnea-hypopnea index (AHI). AHI is a widely-used screening and diagnostic tool for sleep-disordered breathing. However, such analysis tends to underestimate the AHI, since for significant periods during the session the patient may not have been asleep. The result is that screening patients based on the AHI returned by such analysis tends to miss the patients whose sleep during the monitoring session was patchy, as often occurs for example with insomniacs.

[0016] A more accurate method of estimating the AHI divides the number of apneas and hypopneas by the number of hours the patient was asleep during the session. To compute the AHI in this way requires the analysis to detect when the patient was asleep. Detecting sleep/wake state purely from nasal pressure (or indeed from the signal for which it is a proxy, nasal flow rate) has proven to be a difficult task, with consequent effects on the accuracy of AHI calculation and hence AHI-based screening, diagnosis, and monitoring.

[0017] A need therefore exists for an improved SDB screening / monitoring / diagnosis system that more accurately estimates the total sleep time of the patient.

6 BRIEF SUMMARY OF THE TECHNOLOGY

[0018] The present technology is directed towards providing medical devices used in the monitoring or diagnosis of respiratory disorders having one or more of improved comfort, cost, efficacy, ease of use and manufacturability.

[0019] A first aspect of the present technology relates to systems for the screening, diagnosis, or monitoring of a respiratory disorder.

[0020] Another aspect of the present technology relates to methods used in the screening, diagnosis, or monitoring of a respiratory disorder.

[0021] One form of the present technology comprises methods and systems configured to estimate an amount of time the patient was asleep during a monitoring session using actigraphy data gathered during the session. The estimate may be used to compute an index of severity of sleep-disordered breathing (e.g. an apnea-hypopnea index (AHI)) for the session. Optionally, the estimate may take into account respiratory flow rate or effort data gathered during the session.

[0022] According to one aspect of the present invention, there is disclosed a method of estimating a total sleep time of a patient during a monitoring session comprising a plurality of epochs. The method comprises: determining a sleep/wake state of the patient during each epoch of the session using an actigraphy signal of the patient obtained during the monitoring session, and estimating the total sleep time from the sleep/wake state of the patient during each epoch. The determination of the sleep/wake state of the patient during an epoch comprises: determining an activity count for each epoch from the actigraphy signal, and determining the sleep/wake state of the patient during the epoch to be “wake” if a ratio of the activity count for the epoch to the activity count for a preceding epoch is greater than a first activity threshold.

[0023] According to another aspect of the present invention, there is disclosed a system for estimating a total sleep time of a patient during a monitoring session comprising a plurality of epochs. The system comprises: an actigraph configured to generate an actigraphy signal representing acceleration of the actigraph in each of three orthogonal axes; and a processor programmed to: determine an activity count for each epoch from the actigraphy signal; determine a sleep/wake state of the patient during each epoch to be “wake” if a ratio of the activity count for the epoch to the activity count for a preceding epoch is greater than a first activity threshold; and estimate the total sleep time from the sleep/wake state of the patient during each epoch.

[0024] Of course, portions of the aspects may form sub-aspects of the present technology. Also, various ones of the sub-aspects and/or aspects may be combined in various manners and also constitute additional aspects or sub-aspects of the present technology.

[0025] Other features of the technology will be apparent from consideration of the information contained in the following detailed description, abstract, drawings and claims.

7 BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The present technology is illustrated by way of example, and not by way of limitation, in the figures of the accompanying drawings, in which like reference numerals refer to similar elements including:

[0027] Fig. 1 shows a patient undergoing polysomnography (PSG).

[0028] Fig. 2 shows an overview of a human respiratory system including the nasal and oral cavities, the larynx, vocal folds, oesophagus, trachea, bronchus, lung, alveolar sacs, heart and diaphragm.

[0029] Fig. 3 is a block diagram of a screening / diagnosis / monitoring system in one form of the present technology.

[0030] Fig. 4 illustrates a nasal cannula that may be used to implement the nasal cannula of the system of Fig. 3.

[0031] Fig. 5 contains a flow chart illustrating a method that may be used to implement the total sleep time estimation algorithm carried out by the system of Fig. 3 in one form of the present technology.

[0032] Fig. 6 contains a flow chart illustrating a method that may be used to implement the total sleep time estimation algorithm carried out by the system of Fig. 3 in an alternative form of the present technology.

[0033] Fig. 7 contains a flow chart illustrating a method that may be used to implement the sleep/wake determination step of the method of Fig. 6.

[0034] Fig. 8 contains a graph of total sleep time (TST) estimated using the algorithm of Fig. 5 plotted against scored TST values approximately 36 monitoring sessions.

[0035] Fig. 9A shows polysomnography of a patient during non-REM sleep breathing normally over a period of about ninety seconds.

[0036] Fig. 9B shows polysomnography of a patient with sleep-disordered breathing over a period of about six minutes.

8 DETAILED DESCRIPTION OF EXAMPLES OF THE TECHNOLOGY

[0037] Before the present technology is described in further detail, it is to be understood that the technology is not limited to the particular examples described herein, which may vary. It is also to be understood that the terminology used in this disclosure is for the purpose of describing only the particular examples discussed herein, and is not intended to be limiting.

[0038] The following description is provided in relation to various examples which may share one or more common characteristics and/or features. It is to be understood that one or more features of any one example may be combinable with one or more features of another example or other examples. In addition, any single feature or combination of features in any of the examples may constitute a further example.

8.1 SCREENING, DIAGNOSIS, MONITORING SYSTEMS

8.1.1 Polysomnography system

[0039] Fig. 1 shows a patient 1000 undergoing polysomnography (PSG). A PSG system comprises a headbox 2000 which receives and records signals from the following sensors: an EOG electrode 2015; an EEG electrode 2020; an ECG electrode 2025; a submental EMG electrode 2030; a snore sensor 2035; a respiratory inductance plethysmogram (respiratory effort sensor) 2040 on a chest band; a respiratory inductance plethysmogram (respiratory effort sensor) 2045 on an abdominal band; an oro-nasal cannula and thermistor 2050; a photoplethysmograph (pulse oximeter) 2055; and a body position sensor 2060. The electrical signals are referred to a ground electrode (ISOG) 2010 positioned in the centre of the forehead.

8.1.2 System for home use

[0040] Fig. 3 is a block diagram illustrating a screening / diagnosis / monitoring system 3000 particularly suitable for home use. The system 3000 comprises a breathing sensor 3010 configured to generate an analog or digital signal indicative of the patient's breathing. In one implementation, the system 3000 comprises a nasal cannula 3020 configured to capture and convey a signal representing the patient's

nasal pressure to the breathing sensor 3010 when connected to the system 3000. The nasal cannula 3020 comprises two prongs or nozzles 3025 configured to be inserted in the patient's nares as illustrated in Fig. 4. The prongs 3025 of the nasal cannula 3020 are connected to a flexible catheter 3028 that is configured to convey the pressure at the nares to the breathing sensor 3010, which is a pressure sensor in this implementation. The nasal pressure signal provided by the breathing sensor 3010 may be taken as representative of the patient's respiratory flow rate Q_r , with appropriate conversion of units.

[0041] The system 3000 further comprises a processor 3030, configured to process and/or analyze the breathing signal derived from the patient's breathing and generated by the sensor 3020 as described below. The processor 3030 processes and/or analyzes the breathing signal in collaboration with the memory 3080.

[0042] The breathing sensor 3010 may be coupled to the processor 3030 via an A/D converter 3040, which converts the analog signal generated by the breathing sensor 3010 to a stream of digital data. Alternatively, if the breathing sensor 3010 is configured to generate a digital signal, the A/D converter 3040 may be omitted.

[0043] The system 3000 may further comprise a respiratory effort sensor 3050 on a chest or abdominal band 3055, similar to the respiratory inductance plethysmogram (respiratory effort sensor) 2040 in the PSG system of Fig. 2. The respiratory effort sensor 3050 is connected to the processor 3030, either directly (for a digital sensor 3050) or via an A/D converter (for an analog sensor 3050) with a predetermined sampling frequency, e.g., 10 Hz. The processor 3030 may be further configured to process and/or analyze the respiratory effort signal generated by the respiratory effort sensor 3050 as described below.

[0044] The system 3000 may further comprise an actigraph 3060. An actigraph is an accelerometer configured to generate signals representing the acceleration of the actigraph in each of three orthogonal axes, labelled X, Y, and Z, and defined in relation to the axes of the actigraph. These three signals are collectively referred to as the actigraphy signal. Actigraphy has been widely used by researchers as an input to sleep/wake determination in a variety of scenarios, most frequently for the evaluation of insomnia, sleep state misperception, and circadian rhythm disorders. Because

actigraphy is not acquired using electrophysiology, but rather by quantification of movement, disagreement between sleep/wake states derived from PSG and actigraphy is possible when patients frequently toss and turn during sleep or experience motionless awakenings. Several algorithms for analysis of actigraphy have been developed and applied in different situations; concordance of sleep/wake results obtained from these algorithms with those obtained using the gold-standard PSG is generally good.

[0045] The actigraph 3060 is configured to be mounted on a convenient location on the patient's body, for example on the patient's trunk. The actigraph 3060 is connected to the processor 3030, either directly (for a digital actigraph 3060) or via an A/D converter (for an analog actigraph 3060) with a predetermined sampling frequency, e.g. 10 Hz. Either the actigraph 3060 (if digital) or the A/D converter is said to generate actigraphy data or an actigraphy signal comprising samples at a certain sampling frequency. The processor 3030 may be further configured to process and/or analyze the actigraphy signal generated by the actigraph 3060 as described below.

[0046] The system 3000 may further comprise a power source 3090, such as a battery, configured to generate power for the other components of the system 3000. The system may also use other power sources such as that available via an A/C outlet.

[0047] As mentioned above, the signal processing / analysis may be carried out by the processor 3030. The processor may comprise a processor specifically programmed to carry out the monitoring/processing/analysis/diagnosis or any of the other methods discussed herein, including those relating to, for example, SDB. In such implementations of the system 3000, the processing may be embodied as computer programs stored in the memory 3080. Such computer programs may comprise instructions and/or data to carry out the algorithms or methods disclosed herein. The programs may be stored in a memory location, e.g., ROM, and then get loaded in RAM during run time as needed. The processor may also comprise a digital signal processor or an application specific integrated circuit appropriately programmed (e.g., with code downloaded from a storage location or burnt into the hardware) to implement the algorithms and methods discussed herein.

[0048] The processor that carries out the signal processing/analysis may alternatively form part of a remote computing device (not shown). In one such implementation, processor 3030 may be a “local processor” configured to relay the signals generated by the various sensors, e.g. the breathing sensor 3010, to a processor associated with a remote computing device (“the remote processor”), either wirelessly or by wired connection, via a communication interface 3070. In such an implementation, the system 3000 may communicate via BlueTooth or WiFi with the remote computing device, for example a laptop, mobile phone, tablet or, more generally, any computing device with sufficient processing capability. In another such implementation, the processor 3030 may store the various signals in the memory 3080, which may be removable from the system 3000 (such as for example a memory card or external hard drive, etc.). In such an implementation, the removed memory 3080 may be inserted in an interface of the remote computing device, which is configured to retrieve the stored signals from the memory 3080 for processing / analysis by its processor (the remote processor). The memory that stores the actigraph data or signals used by a processor in performing the algorithms or methods described herein may therefore be different than the memory that stores the program used to store instructions, or in some implementations it could be the same memory.

[0049] The signal processing/analysis may also be shared between the local processor 3030 and the processor of the remote computing device, such that some portion of the signal processing/analysis is carried out by the local processor 3030, which then sends intermediate analysis results to the remote computing device so that the remainder of the signal processing / analysis may be carried out by the processor of the remote computing device.

[0050] The breathing sensor 3010, processor 3030, A/D converter 3040, communication interface 3070, and memory 3080 of the system 3000 are housed in a housing 3095. The housing 3095 is preferably of a hand-held or pocket size so that it can easily be carried and used by a patient.

8.1.3 Signal processing / analysis

[0051] The following sections describe various aspects of the signal processing / analysis carried out on the various signals as part of the screening / diagnosis / monitoring function of the system 3000.

8.1.3.1 Total sleep time estimation

[0052] According to some aspects of the disclosure, a total sleep time estimation method may use an activity-based classifier capable of discriminating sleep from wakefulness periods during a monitoring session while the patient is in bed. The total sleep time estimation method may be a supervised learning type method that uses a training dataset to “learn” parameters. In one implementation, the total sleep time estimation method takes the triaxial acceleration signals making up the actigraphy signal generated by the actigraph 3060 during the monitoring session, filters them appropriately, and partitions the monitoring session into epochs. A count of physical activity is estimated for each epoch from the filtered actigraphy signal. Each epoch is classified into a binary state, either “sleep” or “wake”, based on the activity counts. The classification uses activity thresholds that may, for example, have been optimised via cross-validation on previously “scored” training data.

[0053] Fig. 5 contains a flow chart illustrating an example of a total sleep time estimation method 500, according to one form of the present technology. Method 500 may be implemented, for example, by local processor 3030 shown in Figure 3 or by a remote processor, or by a combination of local processor 3030 and a remote processor, as described above.

[0054] The method 5000 starts at step 5010, which pre-processes the actigraphy signal. Pre-processing the actigraphy signal may include, for example, removing any drift in the baseline of the accelerometer. In accordance with some implementations, pre-processing may include de-trending the actigraphy signal. Step 5020 then filters the pre-processed actigraphy signal. Each of steps 5010 to 5030 are carried out independently on the three “channels” of the actigraphy signal, that is, the acceleration values in each of the three axes (X, Y, and Z).

[0055] After pre-processing, the resulting pre-processed signal may be filtered, as shown at 5020. Filtering may include, for example, reducing or removing components of the actigraphy signal unrelated to gross bodily motion. In one implementation, step 5020 comprises band-pass filtering the de-trended actigraphy signal within the range 0.5 Hz to 4.5 Hz, which corresponds to a range of normal gross bodily movement. Step 5020 may also comprise magnitude normalisation, in which the filtered actigraphy signal is divided by its 95th percentile value.

[0056] Step 5030 follows, which partitions each channel into epochs of predetermined durations. In one implementation, each epoch is of duration 30 seconds, and each epoch overlaps the previous and succeeding epoch by ten seconds in order to minimise marginal cases. It is noted, however, that other epoch durations and overlap ranges may be selected.

[0057] The next step 5040 determines an activity count A_n for each epoch n . In one implementation, step 5040 rectifies (e.g., takes the absolute value of) the three filtered actigraphy channels, sums the three rectified channels to obtain a single actigraphy signal, and computes the activity count A_n for each epoch as a quadratic mean (RMS value or root mean square) of the summed signal over the epoch.

[0058] The method 5000 then proceeds to step 5050, which determines a sleep/wake state of each epoch n based on its activity count A_n and that of its preceding epoch (A_{n-1}). In one implementation, if the ratio of A_n to A_{n-1} exceeds a first activity threshold T_1 , the sleep/wake state of epoch n is determined to be “wake”; otherwise, it is “sleep”. In such an implementation, the patient is determined to be asleep if the activity count has not increased substantially since the previous epoch, regardless of its absolute level. In another implementation, if the activity count A_n is greater than a second activity threshold T_2 , the sleep/wake state of epoch n is determined to be “wake”, otherwise, it is “sleep”. In yet another implementation, if either of these criteria are met, the sleep/wake state of epoch n is determined to be “wake”, otherwise, it is “sleep”.

[0059] The activity thresholds T_1 and T_2 may be determined from previous actigraphy data that has been “scored” (i.e. sleep/wake state determined) by some other means, e.g., manually using simultaneous PSG data. In one implementation, the optimisation of the activity thresholds may be carried out by six-fold cross-validation, maximising cross-correlation coefficients between the output of the method 5000 and the scored actigraphy data. In one such implementation on typical scored actigraphy data, the optimal value of the first activity threshold T_1 was found to be 1.7, and the optimal value of the second activity threshold T_2 was found to be the 94th percentile of activity counts over the scored data set. However, values of the first activity threshold in the range [1.3, 2.0], and of the second activity threshold in the range between the 65th and the 98th percentile, may be used with reasonable efficacy.

[0060] The final step 5060 estimates the total sleep time (TST) from the determined sleep/wake state of each epoch. Since the epochs are overlapping, step 5060 does not simply count the number of sleep-determined epochs and multiply by the duration of each epoch. Rather, step 5060 counts the number of time instants corresponding to actigraphy signal samples that have been determined to be part of an epoch whose sleep/wake state was determined to be “sleep”, and divides by the sampling frequency of the actigraph 3060 or its A/D converter (whichever of these supplies the actigraphy signal samples to the signal processing / analysis). The result is a TST value in seconds.

[0061] An alternative implementation of the total sleep time estimation method uses either the respiratory flow rate signal from the breathing sensor 3010 or the respiratory effort signal from the respiratory effort sensor 3050 in addition to the actigraphy signal from the actigraph 3060.

[0062] Fig. 6 contains a flow chart illustrating a method 6000 that may be used to implement the total sleep time estimation method according to the alternative implementation. Steps 6010 to 6040 of the method 6000 are the same as the corresponding steps 5010 to 5040 in the method 5000.

[0063] Step 6050, like step 5050, determines a sleep/wake state of each epoch n . Step 6050, like step 5050, uses the activity count A_n of the epoch and that of its preceding epoch (A_{n-1}). Unlike step 5050, step 6050 further takes into account either the respiratory flow rate signal from the breathing sensor 3010 or the respiratory effort signal from the respiratory effort sensor 3050. This additional signal provides further insights into the state of the patient, particularly during epochs when the patient may have been awake but relatively motionless.

[0064] Fig. 7 contains a flow chart illustrating a method 7000 that may be used to implement the total sleep time estimation step 6050 of the method 6000 for a current epoch n . The method 7000 is described in terms of the respiratory flow rate signal from the breathing sensor 3010, but it should be understood that the method 7000 may also be carried out with the respiratory effort signal from the respiratory effort sensor 3050 substituted for the respiratory flow rate signal.

[0065] The method 7000 starts at step 7010, which checks, like step 5050, whether the ratio (A_n / A_{n-1}) of the activity count A_n of the current epoch to the activity count A_{n-1} of the preceding epoch exceeds a first activity threshold T_1 , or whether the activity count A_n of the current epoch is greater than a second activity threshold T_2 . If so (“Y”), step 7020 determines the sleep/wake state of the current epoch n to be “wake”. The same activity thresholds T_1 and T_2 may be used in step 7010 as in step 5050.

[0066] However, if neither of these conditions holds (“N”), although the patient is relatively immobile, the method 7000 makes further checks before determining the sleep/wake state. In particular, step 7030 determines whether the quality of the respiratory flow rate signal during the current epoch is sufficient. If not (“N”), step 7040 determines the sleep/wake state of the current epoch to be “unknown”. Otherwise (“Y”), step 7050 determines whether the respiratory flow rate signal during the current epoch is stable. To test for stability, step 7050 tests whether the variability (e.g. standard deviation) over the epoch of one or more of the following respiratory-flow-rate-related variables is below a threshold:

- Tidal volume;
- Inspiratory time;
- Respiratory rate;
- Inspiratory peak flow;
- Expiratory peak flow location;
- Time since last breath.

[0067] If the respiratory flow rate signal during the current epoch is stable (“Y”), step 7060 determines the sleep/wake state of the current epoch to be “sleep”. Otherwise (“N”), step 7070 determines whether the respiratory flow rate signal contains an indication that an SDB event took place during the current epoch. “SDB events” in this context refers to breathing events related to sleep-disordered breathing and may include snore, flow limitation, respiratory-effort-related arousal, obstructive hypopnea, and obstructive apnea. Methods of detecting these various kinds of SDB events are described below. If so (“Y”), step 7060 determines the sleep/wake state of the current epoch to be “sleep”. Otherwise, step 7080 determines the sleep/wake state of the current epoch to be “wake”.

[0068] The final step 6060 of the method 6000 estimates the total sleep time (TST) from the sleep/wake determination of each epoch in the same way as step 5060 of the method 5000.

8.1.3.2 Apnea / hypopnea detection

[0069] The apnea / hypopnea detection algorithm receives as an input a signal representing the respiratory flow rate from the breathing sensor 3010 and provides as an output a flag that indicates that an apnea or a hypopnea has been detected.

[0070] In one form, an apnea will be said to have been detected when a function of respiratory flow rate falls below a flow rate threshold for a predetermined period of time. The function may determine a peak flow rate, a relatively short-term mean flow rate, or a flow rate intermediate of relatively short-term mean and peak flow rate, for example an RMS flow rate. The flow rate threshold may be a relatively long-term measure of flow rate.

[0071] In one form, a hypopnea will be said to have been detected when a function of respiratory flow rate falls below a second flow rate threshold for a predetermined period of time. The function may determine a peak flow, a relatively short-term mean flow rate, or a flow rate intermediate of relatively short-term mean and peak flow rate, for example an RMS flow rate. The second flow rate threshold may be a relatively long-term measure of flow rate. The second flow rate threshold is greater than the flow rate threshold used to detect apneas.

8.1.3.3 Detection of snore

[0072] In one form, the snore detection algorithm receives as an input a respiratory flow rate signal from the breathing sensor 3010 and provides as an output a metric of the extent to which snoring is present.

[0073] The snore detection algorithm may comprise the step of determining the intensity of the flow rate signal in the range of 30 - 300 Hz. Further, the snore determination algorithm may comprise a step of filtering the respiratory flow rate signal to reduce background noise, e.g., the sound of airflow in the system from the blower.

[0074] If the intensity of the filtered respiratory flow rate signal exceeds a threshold, snore may be said to be present.

8.1.3.4 Determination of airway patency

[0075] Patency is the degree of the airway being open, or the extent to which the airway is open. A *patent* airway is open. Airway patency may be quantified, for example with a value of one (1) being patent, and a value of zero (0), being closed (obstructed). An apnea or hypopnea that coincides with a patent airway is said to be an open apnea or hypopnea; an apnea or hypopnea that coincides with a closed airway is said to be an obstructive apnea or hypopnea.

[0076] In one form, the airway patency determination algorithm receives as an input a respiratory flow rate signal, and determines the power of the signal in the frequency range of about 0.75 Hz and about 3 Hz. The presence of a peak in this frequency range is taken to indicate an open airway. The absence of a peak is taken to be an indication of a closed airway.

[0077] In one form, airway patency determination algorithm receives as an input a respiratory flow rate signal, and determines the presence or absence of a cardiogenic signal. The absence of a cardiogenic signal is taken to be an indication of a closed airway.

8.1.3.5 Detection of flow limitation

[0078] Flow limitation may be detected from the respiratory flow rate signal as described in United States Provisional Patent Application no. 62/043079, filed 28 August 2014, by ResMed Limited, titled “Diagnosis and treatment of Respiratory Disorders”.

8.1.3.6 Detection of RERAs

[0079] RERAs may be detected from the respiratory flow rate signal as described in PCT Patent Application no. PCT/AU2015/050056, filed 13 February 2015 by ResMed Limited, titled “Diagnosis and treatment of Respiratory Disorders”.

8.1.3.7 AHI computation

[0080] The apnea / hypopnea index (AHI) may be computed as follows:

$$\text{AHI} = \frac{\text{number of apneas or hypopneas during the session}}{\text{total sleep time (TST) of the session (in hours)}}$$

[0081] The AHI is therefore represents the number of apnea / hypopnea events experienced (or detected) per hour of sleep. Conventionally, the AHI is taken as an indicator of the severity of a person's sleep-disordered breathing. Consequently, treatment decisions may be based on the value of the AHI computed by the system 3000.

8.1.3.8 Screening / diagnosis / monitoring

[0082] Once computed, the AHI may be used as a screening tool by singling out patients whose AHI during a screening session exceeds a certain threshold for further attention.

[0083] The AHI may also be used to diagnose a patient, that is, categorise the patient by the severity of their SDB, by placing the patient in a category depending on the value of their AHI computed during a diagnosis session.

[0084] Monitoring a patient being treated for SDB using the AHI may involve computing their AHI during each treatment session, and reporting a deterioration of the SDB (i.e., an increase in the AHI). The parameters of the treatment may even be altered depending on the AHI.

8.1.4 Example results

In a sleep study, "scored" actigraphy data from a wrist-mounted actigraph (Actiwatch®, available from Philips Respironics), was recorded in parallel with actigraphy data from a system 3000 with the actigraph 3060 placed on the trunk of each patient. The scored data consisted of 36 monitoring sessions of 29 different patients, comprising a total of over nine million epochs. Table 1 below contains the confusion matrix between sleep/wake states determined by the algorithm 5000 described above (i.e. without the respiratory flow rate or effort data) applied to the actigraphy data recorded by the system 3000, and the scored sleep/wake states of the parallel recorded actigraphy data.

Determined sleep/wake	Scoring
--------------------------	---------

state			
	Sleep	Wake	Total
Sleep	'True sleep' (TS) 8,123,600	'False wake' (FW) 407,650	TS + FW 8,531,250
Wake	'False sleep' (FS) 493,500	'True wake' (TW) 410,850	FS + TW 904,350
Total	TS + FS 8,617,100	FW + TW 818,500	9,435,600

Table 1: Confusion matrix between algorithm results and scoring

[0085] The resulting sensitivity and specificity values are given in Table 2.

Sensitivity (%)	Specificity (%)	Accuracy (%)
94.27	50.20	90.45

Table 2: Sensitivity and specificity of algorithm

[0086] Fig. 8 contains a graph 8000 of TST estimated using the algorithm 5000 on the actigraphy data plotted against the scored TST values for the 36 monitoring sessions. The graph 8000 shows a near-linear correlation between the estimated TST and the scored TST. The overall correlation coefficient was 0.9914. Table 3 gives statistical comparison data between the estimated and scored TST values over the 36 sessions.

	TST (minutes) (Mean $\pm$ std. dev)
Scored	395 $\pm$ 75.08
Estimated	398.9 $\pm$ 76.39

Difference (Mean $\pm$ std. dev)	3.9 $\pm$ 1.31
----------------------------------	----------------

Table 3: Comparison between scored and estimated TST

[0087] Table 3 shows that TST was slightly overestimated by the algorithm 5000 compared to the scored data. This may be because the two actigraphs were placed at different parts of the body (wrist vs trunk). One overestimation scenario could be, for example, when the patient was reading a book, the patient's trunk could be near-motionless but the patient's wrist could undergo motion such as turning over pages etc..

8.2 BREATHING WAVEFORMS

[0088] Fig. 9A shows polysomnography of a patient during non-REM sleep breathing normally over a period of about ninety seconds, with about 34 breaths. The top channel shows oximetry (SpO_2), the scale has a range of saturation from 90 to 99% in the vertical direction. The patient maintained a saturation of about 95% throughout the period shown. The second channel shows quantitative respiratory airflow, and the scale ranges from -1 to +1 LPS in a vertical direction, and with inspiration positive. Thoracic and abdominal movement are shown in the third and fourth channels.

[0089] Fig. 9B shows polysomnography of a patient with SDB over a period of about six minutes. There are eleven signal channels from top to bottom with a 6 minute horizontal span. The top two channels are both EEG (electroencephalogram) from different scalp locations. Periodic spikes in the second EEG represent cortical arousal and related activity. The third channel down is submental EMG (electromyogram). Increasing activity around the time of arousals represents genioglossus nerve recruitment. The fourth & fifth channels are EOG (electro-oculogram). The sixth channel is an electrocardiogram. The seventh channel shows pulse oximetry (SpO_2) with repetitive desaturations to below 70% from about 90%. The eighth channel is respiratory airflow using nasal cannula connected to a differential pressure transducer. Repetitive apneas of 25 to 35 seconds alternate with 10 to 15 second bursts of recovery breathing coinciding with EEG arousal and increased EMG activity. The ninth channel shows movement of chest and the tenth shows movement of abdomen. The abdomen shows a crescendo of movement over

the length of the apnea leading to the arousal. Both become untidy during the arousal due to gross body movement during the recovery hyperpnea. The apneas are therefore obstructive, and the condition is severe. The lowest channel is posture, and in this example it does not show change.

8.3 GLOSSARY

[0090] For the purposes of the present technology disclosure, in certain forms of the present technology, one or more of the following definitions may apply. In other forms of the present technology, alternative definitions may apply.

8.3.1 General

[0091] *Air*: In certain forms of the present technology, air may be taken to mean atmospheric air, and in other forms of the present technology air may be taken to mean some other combination of breathable gases, e.g. atmospheric air enriched with oxygen.

[0092] *Ambient*: In certain forms of the present technology, the term ambient will be taken to mean (i) external of the treatment system or patient, and (ii) immediately surrounding the treatment system or patient.

[0093] *Respiratory Pressure Therapy (RPT)*: The application of a supply of air to an entrance to the airways at a treatment pressure that is typically positive with respect to atmosphere.

[0094] *Continuous Positive Airway Pressure (CPAP) therapy*: Respiratory pressure therapy in which the treatment pressure is approximately constant through a respiratory cycle of a patient. In some forms, the pressure at the entrance to the airways will be slightly higher during exhalation, and slightly lower during inhalation. In some forms, the pressure will vary between different respiratory cycles of the patient, for example, being increased in response to detection of indications of partial upper airway obstruction, and decreased in the absence of indications of partial upper airway obstruction.

[0095] *Patient*: A person, whether or not they are suffering from a respiratory disease.

[0096] *Automatic Positive Airway Pressure (APAP) therapy*: CPAP therapy in which the treatment pressure is automatically adjustable, e.g. from breath to breath, between minimum and maximum limits, depending on the presence or absence of indications of SDB events.

8.3.2 Aspects of the respiratory cycle

[0097] *Apnea*: According to some definitions, an apnea is said to have occurred when flow falls below a predetermined threshold for a duration, e.g. 10 seconds. An obstructive apnea will be said to have occurred when, despite patient effort, some obstruction of the airway does not allow air to flow. A central apnea will be said to have occurred when an apnea is detected that is due to a reduction in breathing effort, or the absence of breathing effort, despite the airway being patent. A mixed apnea occurs when a reduction or absence of breathing effort coincides with an obstructed airway.

[0098] *Breathing rate*: The rate of spontaneous respiration of a patient, usually measured in breaths per minute.

[0099] *Duty cycle*: The ratio of inhalation time, T_i to total breath time, T_{tot} .

[0100] *Effort (breathing)*: Breathing effort will be said to be the work done by a spontaneously breathing person attempting to breathe.

[0101] *Expiratory portion of a breathing cycle*: The period from the start of expiratory flow to the start of inspiratory flow.

[0102] *Flow limitation*: Flow limitation will be taken to be the state of affairs in a patient's respiration where an increase in effort by the patient does not give rise to a corresponding increase in flow. Where flow limitation occurs during an inspiratory portion of the breathing cycle it may be described as inspiratory flow limitation. Where flow limitation occurs during an expiratory portion of the breathing cycle it may be described as expiratory flow limitation.

[0103] *Flow rate*: The instantaneous volume (or mass) of air delivered per unit time. While flow rate and ventilation have the same dimensions of volume or mass per unit time, flow rate is measured over a much shorter period of time. In some

cases, a reference to flow rate will be a reference to a scalar quantity, namely a quantity having magnitude only. In other cases, a reference to flow rate will be a reference to a vector quantity, namely a quantity having both magnitude and direction. Where it is referred to as a signed quantity, a flow rate may be nominally positive for the inspiratory portion of a breathing cycle of a patient, and hence negative for the expiratory portion of the breathing cycle of a patient. Flow rate will be given the symbol Q . 'Flow rate' is sometimes shortened to simply 'flow'. Total flow rate, Q_t , is the flow rate of air leaving the RPT device. Vent flow rate, Q_v , is the flow rate of air leaving a vent to allow washout of exhaled gases. Leak flow rate, Q_l , is the flow rate of leak from a patient interface system. Respiratory flow rate, Q_r , is the flow rate of air that is received into the patient's respiratory system.

[0104] *Hypopnea*: Preferably, a hypopnea will be taken to be a reduction in flow, but not a cessation of flow. In one form, a hypopnea may be said to have occurred when there is a reduction in flow below a threshold rate for a duration. A central hypopnea will be said to have occurred when a hypopnea is detected that is due to a reduction in breathing effort. In one form in adults, either of the following may be regarded as being hypopneas:

- (i) a 30% reduction in patient breathing for at least 10 seconds plus an associated 4% desaturation; or
- (ii) a reduction in patient breathing (but less than 50%) for at least 10 seconds, with an associated desaturation of at least 3% or an arousal.

[0105] *Hyperpnea*: An increase in flow to a level higher than normal flow rate.

[0106] *Inspiratory portion of a breathing cycle*: The period from the start of inspiratory flow to the start of expiratory flow will be taken to be the inspiratory portion of a breathing cycle.

[0107] *Patency (airway)*: The degree of the airway being open, or the extent to which the airway is open. A *patent* airway is open. Airway patency may be quantified, for example with a value of one (1) being patent, and a value of zero (0), being closed (obstructed).

[0108] *Positive End-Expiratory Pressure (PEEP)*: The pressure above atmosphere in the lungs that exists at the end of expiration.

[0109] *Peak flow rate (Q_{peak})*: The maximum value of flow rate during the inspiratory portion of the respiratory flow waveform.

[0110] *Respiratory flow rate, airflow rate, patient airflow rate, respiratory airflow rate (Q_r)*: These synonymous terms may be understood to refer to the RPT device's estimate of respiratory airflow rate, as opposed to "true respiratory flow" or "true respiratory airflow", which is the actual respiratory flow rate experienced by the patient, usually expressed in litres per minute.

[0111] *Tidal volume (V_t)*: The volume of air inhaled or exhaled during normal breathing, when extra effort is not applied.

[0112] *(inhalation) Time (T_i)*: The duration of the inspiratory portion of the respiratory flow rate waveform.

[0113] *(exhalation) Time (T_e)*: The duration of the expiratory portion of the respiratory flow rate waveform.

[0114] *(total) Time (T_{tot})*: The total duration between the start of the inspiratory portion of one respiratory flow rate waveform and the start of the inspiratory portion of the following respiratory flow rate waveform.

[0115] *Typical recent ventilation*: The value of ventilation around which recent values over some predetermined timescale tend to cluster, that is, a measure of the central tendency of the recent values of ventilation.

[0116] *Upper airway obstruction (UAO)*: includes both partial and total upper airway obstruction. This may be associated with a state of flow limitation, in which the level of flow increases only slightly or may even decrease as the pressure difference across the upper airway increases (Starling resistor behaviour).

8.4 OTHER REMARKS

[0117] A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the

facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in Patent Office patent files or records, but otherwise reserves all copyright rights whatsoever.

[0118] Unless the context clearly dictates otherwise and where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit, between the upper and lower limit of that range, and any other stated or intervening value in that stated range is encompassed within the technology. The upper and lower limits of these intervening ranges, which may be independently included in the intervening ranges, are also encompassed within the technology, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the technology.

[0119] Furthermore, where a value or values are stated herein as being implemented as part of the technology, it is understood that such values may be approximated, unless otherwise stated, and such values may be utilized to any suitable significant digit to the extent that a practical technical implementation may permit or require it.

[0120] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present technology, a limited number of the exemplary methods and materials are described herein.

[0121] When a particular material is identified as being used to construct a component, obvious alternative materials with similar properties may be used as a substitute. Furthermore, unless specified to the contrary, any and all components herein described are understood to be capable of being manufactured and, as such, may be manufactured together or separately.

[0122] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include their plural equivalents, unless the context clearly dictates otherwise.

[0123] All publications or other materials (e.g., unpublished patent applications) mentioned herein are incorporated herein by reference in their entirety to disclose and describe the methods and/or materials which are the subject of those publications. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present technology is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed.

[0124] The terms "comprises" and "comprising" should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced.

[0125] The subject headings used in the detailed description are included only for the ease of reference of the reader and should not be used to limit the subject matter found throughout the disclosure or the claims. The subject headings should not be used in construing the scope of the claims or the claim limitations.

[0126] Although the technology herein has been described with reference to particular examples, it is to be understood that these examples are merely illustrative of the principles and applications of the technology. In some instances, the terminology and symbols may imply specific details that are not required to practice the technology. For example, although the terms "first" and "second" may be used, unless otherwise specified, they are not intended to indicate any order but may be utilised to distinguish between distinct elements. Furthermore, although process steps in the methodologies may be described or illustrated in an order, such an ordering is not required. Those skilled in the art will recognize that such ordering may be modified and/or aspects thereof may be conducted concurrently or even synchronously.

[0127] It is therefore to be understood that numerous modifications may be made to the illustrative examples and that other arrangements may be devised without departing from the spirit and scope of the technology.

8.5 REFERENCE SIGNS LIST

patient	1000
headbox	2000
ground electrode	2010
EOG electrode	2015
EEG electrode	2020
ECG electrode	2025
submental EMG electrode	2030
snore sensor	2035
respiratory inductance plethysmogram	2040
respiratory inductance plethysmogram	2045
oro-nasal cannula	2050
photoplethysmograph	2055
body position sensor	2060
screening / diagnosis / monitoring system	3000
breathing sensor	3010
nasal cannula	3020
prongs	3025
flexible catheter	3028
processor	3030
A/D converter	3040
respiratory effort sensor	3050
abdominal band	3055
actigraph	3060
communication interface	3070
memory	3080
energy source	3090
housing	3095
method	5000
step	5010
step	5020
step	5030
step	5040
step	5050
step	5060
method	6000
step	6010
step	6050
step	6050
step	6060
method	7000
step	7010
step	7020
step	7030
step	7040

step	7050
step	7060
step	7070
step	7080
graph	8000

9 CLAIMS

1. A method of estimating a total sleep time of a patient during a monitoring session comprising a plurality of epochs, the method comprising:

determining a sleep/wake state of the patient during each epoch of the session using an actigraphy signal obtained during the monitoring session of the patient, and

estimating the total sleep time from the sleep/wake state of the patient during each epoch,

wherein the determining the sleep/wake state of the patient during an epoch comprises:

determining an activity count for each epoch from the actigraphy signal,
and

determining the sleep/wake state of the patient during the epoch to be “wake” if a ratio of the activity count for the epoch to the activity count for a preceding epoch is greater than a first activity threshold.

2. The method of claim 1, wherein determining the sleep/wake state of the patient during an epoch further comprises determining the sleep/wake state to be “wake” if the activity count of the epoch is greater than a second activity threshold.

3. The method of claim 1, wherein the determining the sleep/wake state further depends on a respiratory flow rate signal of the patient.

4. The method of claim 3, wherein the determining the sleep/wake state further comprises determining the sleep/wake state to be “sleep” if the respiratory flow rate signal is stable during the epoch.

5. The method of claim 3, wherein the determining the sleep/wake state further comprises determining the sleep/wake state to be “sleep” if the respiratory flow rate signal contains an indication that an SDB event took place during the epoch.

6. The method of claim 1, wherein the determining the sleep/wake state further depends on a respiratory effort signal of the patient.
7. The method of claim 6, wherein the determining the sleep/wake state further comprises determining the sleep/wake state to be “sleep” if the respiratory effort signal is stable during the epoch.
8. The method of claim 6, wherein the determining the sleep/wake state further comprises determining the sleep/wake state to be “sleep” if the respiratory effort signal contains an indication that an SDB event took place during the epoch.
9. The method of any one of claim 5 and claim 8, wherein the SDB event comprises one of snore, flow limitation, respiratory-effort-related arousal, obstructive hypopnea, and obstructive apnea.
10. A method according to any one of claims 1 to 9, further comprising computing an index of severity of sleep-disordered breathing of the patient from the estimated total sleep time.
11. A method according to claim 10, wherein the computing the index comprises
 - detecting apneas and hypopneas during the session, and
 - dividing a number of detected apneas and hypopneas during the session by the estimated total sleep time.
12. A method according to any of claims 1 to 11, wherein the determining an activity count for an epoch comprises:
 - rectifying each channel of the actigraphy signal,
 - summing the rectified channels to obtain a single actigraphy signal, and
 - computing a root mean squared value of the single actigraphy signal over the epoch.
13. A system for estimating a total sleep time of a patient during a monitoring session comprising a plurality of epochs, the system comprising:

an actigraph configured to generate an actigraphy signal representing acceleration of the actigraph in each of three orthogonal axes; and

a processor programmed to:

determine an activity count for each epoch from the actigraphy signal;

determine a sleep/wake state of the patient during each epoch to be “wake” if a ratio of the activity count for the epoch to the activity count for a preceding epoch is greater than a first activity threshold; and

estimate the total sleep time from the sleep/wake state of the patient during each epoch.

14. A system according to claim 13, further comprising a breathing sensor configured to generate a signal indicative of the patient's breathing, wherein determination of the sleep/wake state further depends on the generated signal.

15. A system according to claim 13, further comprising a respiratory effort sensor configured to generate a signal indicative of the patient's respiratory effort, wherein determination of the sleep/wake state further depends on the generated respiratory effort signal.

16. A system according to claim 13, wherein the processor forms part of a remote computing device.


17. A system according to claim 16, further comprising:

a communication interface, and


a local processor configured to relay the actigraphy signal to the processor of the remote computing device via the communication interface.

18. A system according to claim 16, further comprising a removable memory configured to store the actigraphy signal.

FIG. 1



2/10

**FIG. 2**

3/10




FIG. 3

4/10




FIG. 4

5/10





FIG. 5

**FIG. 6**




FIG. 7

8/10




FIG. 8




FIG. 9A




FIG. 9B

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/AU2016/050346

A. CLASSIFICATION OF SUBJECT MATTER

A61B 5/00 (2006.01) A61B 5/11 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPODOC, WPIAP, TXTE, MEDLINE, INSPEC: IPC: A61B5; CPC: A61B5/4806/LOW, A61B5/4809, A61B5/1118, A61B2562/0219, A61B5/1135, A61B5/4812; Keywords: sleep, time, actigraphy, accelerometer, activity, threshold, wake, state, detect, and like terms; Applicant and inventor names searched with EPODOC. **ESPACENET and GOOGLE PATENTS:** Keywords: estimate, sleep, time, apnoea, actigraphy, accelerometer, activity, level, movement, and like terms. **PUBMED and GOOGLE SCHOLAR:** Keywords: total sleep time, actigraphy, activity count, threshold, ratio, and like terms. Applicant(s)/Inventor(s) name searched in internal databases provided by IP Australia.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	



Further documents are listed in the continuation of Box C



See patent family annex

* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search 20 July 2016		Date of mailing of the international search report 20 July 2016
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA Email address: pct@ipaustalia.gov.au		Authorised officer Vivian Cheung AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No. 0262832414

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/AU2016/050346
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	US 2012/0232414 A1 (MOLLICONE et al.) 13 September 2012 paragraphs [0031-0032], [0034], [0059-0060], [0066-0067] paragraphs [0031-0032], [0034], [0059-0060], [0066-0067]	1-2, 10-13, 16-18 3-9, 14-15
X Y	US 2014/0364770 A1 (MOTOROLA MOBILITY LLC) 11 December 2014 paragraphs [0003], [0023-0025], [0040-0041], [0045-0047], [0055-0056] paragraphs [0003], [0023-0025], [0040-0041], [0045-0047], [0055-0056]	1-2, 10-13, 16-18 3-9, 14-15
X Y	US 2007/0129769 A1 (BOURGET et al.) 07 June 2007 paragraphs [0062-0063], [0067] paragraphs [0062-0063], [0067]	1-2, 10-13, 16-18 3-9, 14-15
Y	US 2014/0088373 A1 (RESMED SENSOR TECHNOLOGIES LIMITED) 27 March 2014 paragraphs [0011], [0024-0032]	3-9, 14-15

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/AU2016/050346	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
US 2012/0232414 A1	13 September 2012	US 2012232414 A1	13 Sep 2012
		US 8568330 B2	29 Oct 2013
US 2014/0364770 A1	11 December 2014	US 2014364770 A1	11 Dec 2014
		WO 2014197678 A2	11 Dec 2014
US 2007/0129769 A1	07 June 2007	US 2007129769 A1	07 Jun 2007
		EP 1962686 A1	03 Sep 2008
		EP 1962686 B1	11 Nov 2009
		US 2007129622 A1	07 Jun 2007
		US 8016776 B2	13 Sep 2011
		US 2011313261 A1	22 Dec 2011
		US 8444578 B2	21 May 2013
		WO 2007064642 A1	07 Jun 2007
US 2014/0088373 A1	27 March 2014	US 2014088373 A1	27 Mar 2014
		AU 2013318046 A1	12 Mar 2015
		CA 2883656 A1	27 Mar 2014
		CN 104812300 A	29 Jul 2015
		EP 2897526 A1	29 Jul 2015
		JP 2015532855 A	16 Nov 2015
		KR 20150058344 A	28 May 2015
		US 2015230750 A1	20 Aug 2015
		WO 2014047310 A1	27 Mar 2014
End of Annex			
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001. Form PCT/ISA/210 (Family Annex)(July 2009)			

专利名称(译)	用于筛查，诊断和监测睡眠呼吸紊乱的系统和方法		
公开(公告)号	EP3294115A4	公开(公告)日	2018-12-12
申请号	EP2016791824	申请日	2016-05-09
[标]申请(专利权)人(译)	雷斯梅德有限公司		
申请(专利权)人(译)	瑞思迈有限公司		
当前申请(专利权)人(译)	瑞思迈有限公司		
[标]发明人	WANG NING		
发明人	WANG, NING		
IPC分类号	A61B5/00 A61B5/11		
CPC分类号	A61B5/4809 A61B5/036 A61B5/04004 A61B5/0488 A61B5/087 A61B5/097 A61B5/1118 A61B5/113 A61B5/4519 A61B5/4815 A61B5/4818 A61B5/6819 A61B2562/0247		
优先权	62/160937 2015-05-13 US		
其他公开文献	EP3294115A1		
外部链接	Espacenet		

摘要(译)

公开了一种用于监测/筛选/诊断受试者或患者的睡眠或苏醒状态的方法和系统。该方法通常包括在一个或多个睡眠期间监测患者的活动，该睡眠期包括称为时期的多个间隔。使用在监测会话期间获得的活动记录数据在会话的每个时期期间确定受试者的睡眠/苏醒状态。活动记录数据提供有关患者在一个时期内活动的信息。基于时期期间的活动计数与前一时期的活动计数的比率来确定睡眠或苏醒状态。如果该比率大于第一活动阈值，则可以由例如系统提供“唤醒”指示。可替代地或另外地，如果在时期期间的活动计数大于阈值，则可以确定“唤醒”指示。